Biotech company, Biora Therapeutics, Inc. (BIOR), announced on Thursday that it has achieved positive interim results from the single-ascending dose clinical trial of BT-600.
The BT-600 is a drug-device combination consisting of an orally administered NaviCap device, for the treatment of patients with ulcerative colitis or UC.
UC is a chronic disease with symptoms such as abdominal pain, increased bowel movements, stool urgency, and rectal bleeding, eventually damaging the colon.
The interim results revealed that all pharmacokinetic endpoints, regarding comparison of 5 mg and 10 mg doses of tofacitinib, to placebo, were met in all study participants without any serious adverse events.
Following the announcement, Biora's stock is trading at $0.69, down 6.56 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.